GlassScriptPhysician profile
John F Dongas
NPI 1003864331
$6,590.36
in general payments reported to CMS, 2019-2025
35 companies · $25.93 in 2025
The $25.93 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,230 · 2020: $474 · 2021: $1,340 · 2022: $2,130 · 2023: $1,390 · 2025: $25.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Preventric Diagnostics, INC. | $1,272.75 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $526.90 | 2019-2023 | Lifevest |
| Boston Scientific Corporation | $499.69 | 2019-2025 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor, Farapulse |
| Novartis Pharmaceuticals Corporation | $491.57 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $479.89 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $368.86 | 2020-2023 | Xarelto |
| Pfizer INC. | $335.61 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $259.73 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $250.62 | 2019-2023 | Farxiga, Lynparza, Wainua |
| Regeneron Healthcare Solutions, INC. | $237.62 | 2019-2023 | Praluent, Evkeeza |
| Esperion Therapeutics, INC. | $236.94 | 2020-2023 | Nexletol |
| Novo Nordisk INC | $186.66 | 2019-2023 | Rybelsus, Ozempic |
| Lundbeck LLC | $152.15 | 2019-2020 | |
| Elutia, INC. | $150.14 | 2022 | |
| Amgen INC. | $144.09 | 2019-2023 | Repatha |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $134.22 | 2021-2023 | Verquvo |
| Abbott Laboratories | $123.31 | 2023 | Aveir, Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $101.75 | 2019-2023 | Camzyos |
| Amarin Pharma, INC. | $86.43 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $71.30 | 2022-2023 | Arcalyst |
| Biotronik INC. | $64.62 | 2019-2020 | |
| Chiesi USA, INC. | $64.19 | 2019 | |
| Arbor Pharmaceuticals, INC. | $44.82 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $40.62 | 2023 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $40.44 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.20 | 2021-2023 | |
| Inspire Medical Systems, INC. | $36.00 | 2023 | Inspire |
| Kowa Pharmaceuticals America, INC. | $28.35 | 2019-2021 | |
| Scpharmaceuticals INC. | $23.00 | 2023 | |
| Lantheus Medical Imaging, INC. | $19.97 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $19.86 | 2023 | Inpefa |
| Akcea Therapeutics, INC. | $17.12 | 2019 | |
| Medtronic, INC. | $13.80 | 2021 | |
| Irhythm Technologies, INC. | $13.62 | 2020 | |
| Medtronic Vascular, INC. | $13.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dongas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.